Table 3:
Baseline characteristics of tolvaptan users and the 1:1 matched cohort.
| Tolvaptan, n = 92 | No tolvaptan, n = 92 | P-value | |
|---|---|---|---|
| Age, years | 43 ± 8 | 43 ± 11 | .5 |
| Sex (female), n (%) | 39 (42.4) | 51 (55.4) | .1 |
| Weight, kg | 85.3 ± 13.6 | 80.6 ± 18.4 | .048 |
| Height, m | 1.79 ± 0.10 | 1.77 ± 0.09 | .1 |
| BMI, kg/m2 | 27 ± 4 | 26 ± 5 | .2 |
| Systolic blood pressure, mmHg | 131 ± 14 | 130 ± 11 | .5 |
| Diastolic blood pressure, mmHg | 87 ± 34 | 82 ± 9 | .2 |
| RAAS blockade use, n (%) | 72 (78.3) | 61 (66.3) | .1 |
| Diuretics use, n (%) | 22 (23.9) | 16 (17.4) | .4 |
| Height-adjusted TKV, mL/m | 1071 (742–1495) | 821 (526–1317) | .03 |
| eGFR, mL/min/1.73 m2 | 61 ± 25 | 65 ± 27 | .3 |
| Mayo risk classification, n (%) | .1 | ||
| 1A | 1 (1.1) | 2 (2.2) | |
| 1B | 9 (9.8) | 21 (22.8) | |
| 1C | 29 (31.5) | 31 (33.7) | |
| 1D | 32 (34.8) | 22 (23.9) | |
| 1E | 21 (22.8) | 16 (17.4) | |
| Atypical | |||
| DNA mutation, n (%) | .002 | ||
| PKD1 truncating | 39 (42.4) | 42 (46.7) | |
| PKD1 non-truncating | 16 (17.4) | 24 (26.1) | |
| PKD2 | 6 (6.5) | 15 (16.3) | |
| Other mutation | |||
| No mutation detected | 3 (3.3) | 3 (3.3) | |
| Mutation unknown | 28 (30.4) | 8 (8.7) | |
| Urine osmolality, mOsm/kg | 359 ± 169 | 429 ± 168 | .02 |
| Osmolar intake, mOsm/24 h | 864 ± 320 | 888 ± 243 | .6 |
| Tolvaptan use duration, years | 6.2 ± 4.8 |
Time of baseline characteristics were based on the eGFR measurement closest to the start of (theoretical) treatment. The table shows mean ± standard deviation, median (interquartile range) or number (%).
BMI, body mass index.